0001001316
false
0001001316
2019-11-12
2019-11-12
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): November 12, 2019
TG
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
001-32639
(Commission
File Number)
|
36-3898269
(IRS
Employer Identification No.)
|
2
Gansevoort Street, 9th
Floor
New
York, New York 10014
(Address of
Principal Executive Offices)
(212)
554-4484
(Registrant's
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act.
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act.
☐ Pre-commencement communications
pursuant to Rule 14d-2b under the Exchange Act.
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act.
Title
of Class
|
Trading
Symbol(s)
|
Exchange
Name
|
Common
Stock, par value $0.001
|
TGTX
|
Nasdaq
Capital Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial
Condition.
On
November 12, 2019, TG Therapeutics, Inc. (“TG” or the
“Company”) issued a press release announcing results of
operations for the three and nine months ended September 30, 2019.
The Company will host an investor conference call today, November
12, 2019, at 8:30am ET, during which the Company will provide a
brief overview of its third quarter financial results and provide a
business outlook for the remainder of 2019. A copy of such press
release is being furnished as Exhibit 99.1.
Item 9.01 Financial Statements And Exhibits.
(d)
Exhibits.
Press
release issued by TG Therapeutics, Inc., dated November 12,
2019.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
TG Therapeutics, Inc.
(Registrant)
|
|
|
|
|
|
Date:
November 12, 2019
|
By:
|
/s/
Sean A. Power
|
|
|
|
Sean A.
Power
|
|
|
|
Chief
Financial Officer
|
|